Applied for Oral Free Paper and E-Poster Free Paper.

Before submitting the abstract, you are requested to carefully read the rules regarding abstract submission.

• Abstract(s) may not have been published previously at the time of presentation of the congress.
• Any human experimentation that has been conducted with respect to the submitted abstract(s), should have been conducted according to the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the works should have been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association. Council may enquire further into ethical aspects when evaluating the abstract(s)
• All research involving human and animal subjects require ethical clearance. The IRB number should be declared
• In clinical studies, the authors must state that an Ethical Committee approval has been obtained
• Copyright of the abstract(s) is assigned to Indonesia Association of Tissue Engineering & Cell Therapy (REJASELINDO) any conflicts with any other scientific association will be the sole responsibility of the author(s).
• All abstracts that are published, including figures and tables, are the property of to Indonesia Association of Tissue Engineering & Cell Therapy (REJASELINDO) and are protected by copyright. Requests for reuse of material can be done through
• The REJASELINDO 2026 Scientific Committee office reserves the right to obtain your raw data for statistical evaluation

• All abstract(s) must be submitted in English. Applies also for the title, text body and author affiliations
• Only abstract submitted through the website congress will be considered
• Cancellation or name changes should be notified 1 month prior to the congress by email to rejaselindo-apastb@pharma-pro.com
• Systematic reviews (with or without meta-analysis) can be submitted only when they meet the following standards :
  • The clinical question was clearly defined using a standard PICO (Population, Intervention, Comparison and Outcome) format
  • A comprehensive systematic literature search was carried out an assessment of the risk of bias was made
  • Key findings are clearly described including clinical practice relevance

Authorship

Each quoted author should have contributed substantially to the represented work in terms of conceptual design or analysis writing of article and final approval of the article in order to take public responsibility for the content.

Size

The size of abstracts not more than 300 words and limited to 3,000 characters (including title, body of abstract, spaces tables and graphics). Every picture / graphic count for 500 characters.

Title

The title should clearly define the topic. Do not identify your institution in the title. There is no maximum length for the title. However, the characters in the title are included in your total character count. The first letter of the title will automatically begin with a capital letter. Do type the abstract and title in small letters, except for abbreviations. Do not type the abstract title in capital letters.

Authors

Type the name of the institution, department, city and country in English.

Affiliation

Type the name of the institution, department, city and country in English.

Body of the abstract

you can format your abstract using the folowing structure:

• Introduction & objectives
• Materials & methods
• Results
• Conclusion

State the objective of the study, describe the material and methods, summarize the results presenting sufficient details to support of the conclusions reached (not acceptable to state: “The results will be discussed”). Use number for numbers and only very well-known abbreviations e.g. kg, MRI etc. If you must use other abbreviations, you must explain it the first time it appears. You can use the special keys to insert tables, pictures or specific characters.

Proof reading

Verify that your abstract is correct and read the proof carefully that will be automatically shown after you have inserted all data. Keep a printout for your own records.

Editing

Abstract bodies will be published as submitted, except for a simple English spelling check. After submission deadline there is no possibility to edit the abstract anymore.

Submission Deadline

Deadline for abstract submission is January 16th, 2026, 23:59.59 Local Time.

Withdraw Abstract(S)

In case you want to withdraw your abstract after submission, please send an email before January 16th, 2026 to rejaselindo-apastb@pharma-pro.com

Deadline

Should be received at the REJASELINDO 2026 secretariat before January 16th, 2026, After this date will not accepted

Submission

Submit your abstract to the www.rejaselindo-apastb.org before January 16th, 2026